NCT05209529View on ClinicalTrials.gov

Chemo-free BRCA-targeted Neoadjuvant Strategy

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 1, 2024

Primary Completion Date

September 6, 2028

Study Completion Date

July 18, 2030

Conditions

TNBC - Triple-Negative Breast CancerBRCA1 MutationBRCA2 Mutation

Interventions

DRUG

olaparib

olaparib 300 mg per os BID

DRUG

Durvalumab

durvalumab 1500 mg IV Q4 weeks

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK